We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VOYDEYA (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
VOYDEYA
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
danicopan
Registration type
NCE/ NBE
Indication
VOYDEYA is indicated as an add-on to ravulizumab or eculizumab for the treatment of the signs or symptoms of extravascular haemolysis (EVH) in adult patients with paroxysmal nocturnal haemoglobinuria (PNH).